Crinetics Pharmaceuticals, Inc. 4

Camille L. Bedrosian had 16,300 common shares and multiple tranches totaling 113,080 in-the-money stock options in Crinetics Pharmaceuticals, Inc. cashed out or canceled for cash at the $85.00-per-share Vertex merger price on 2026-09-01, resulting in zero remaining ownership.

On September 1, 2026, in connection with the cash acquisition of Crinetics Pharmaceuticals, Inc. by Vertex Pharmaceuticals at $85.00 per share, insider Camille L. Bedrosian had all equity interests cashed out or canceled pursuant to the merger terms. A total of 16,300 shares of common stock (primarily RSUs) were canceled and converted into cash at $85 per share, with 5,925 shares reflected as the post-transaction balance for one common stock line and then reduced to zero as all shares were ultimately converted to cash at closing. In addition, multiple tranches of vested stock options with exercise prices below the $85 merger price were canceled and converted into cash equal to the spread between $85 and the respective exercise prices: 25,000 options at a $16.08 strike ($68.92 per share spread), 17,500 options at $20.23 ($64.77 spread), 17,500 options at $18.29 ($66.71 spread), 17,500 options at $20.32 ($64.68 spread), 12,500 options at $44.71 ($40.29 spread), 10,350 options at $32.33 ($52.67 spread), and 9,730 options at $35.87 ($49.13 spread). These transactions represent merger-driven, non-open-market cash-outs of equity awards rather than discretionary insider buying or selling, and Bedrosian’s beneficial ownership in Crinetics common stock was reduced to zero following the merger close.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059900

Alert Tier

5